AUS
NZ
UK
CA
USA
IND
Summary
- Stocks of Aeterna Zentaris Inc zoomed multiple folds higher on Monday, with nearly 200 per cent.
- The biopharma stock also achieved its 52-week high of C$4.63 yesterday, with a one-year return of 187 per cent.
- The FDA-approved medical test developer’s shares are up 687 per cent this year, with a current price-to-cashflow ratio of 9.90.
Aeterna Zentaris Inc (TSX:AEZS) stock soared as much as 199.3 per cent on Monday, February 8, along with a one-day volume of 3.5 million. The biopharma company has been studying a pre-clinical coronavirus vaccine candidate using an oral bacterial vaccine platform for Julius-Maximilians-University, Germany.
Investors may be taking an interest in this stock on the back of the above development.
The Toronto-based healthcare company also has a Food and Drug Administration (FDA)-approved product Macrilen™, an oral test that detects adult growth hormone insufficiency.
The TSX healthcare index also jumped more than 5.64 per cent on Monday. The index rose over 57 per cent in 2021.
Let us check out the pharma stock’s market fundamentals and financials.
Aeterna Zentaris Inc (TSX:AEZS)
The healthcare stock has gained 687 per cent this year.
The C$ 227-million biotechnology is planning to commercialize its FDA-approved product in Asia and other European countries. It currently operates in North America and Germany.
The stock closed at C$ 4.25 on Monday, February 8. It also touched its 52-week high of C$ 4.63 during intraday trade.
The stock has zoomed more than 1048 per cent from its 52-week low of C$ 0.37. The recent rally has improved its one-year return by 187 per cent, with a price-to-cashflow ratio of 9.90.
In the third quarter of 2020, ended on September 30, 2020, Aeterna Zentaris raised an amount of US$ 19 million, which comprised its direct offering on the Nasdaq exchange of US$ 7.0 million and a public offering of US$ 12 million.
Image Source: Kalkine Group @2020
The pharmaceutical held nearly U$ 21.7 million in cash and cash equivalents as of September 30, 2020. As per the company’s estimations, it has sufficient working capital to execute its research and development (R&D) through 2023.
Its third quarter R&D expenses stood at U$ 1.9 million, down almost 9.5 per cent year-over-year (YoY).
Its fourth quarter results will be out on Tuesday, February 16, 2021.
